Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine
dc.contributor.author | Fischer, Manfred | en_US |
dc.contributor.author | Beierwaltes, William H. | en_US |
dc.contributor.author | Sisson, James C. | en_US |
dc.contributor.author | Khafagi, Frederick A. | en_US |
dc.contributor.author | Shapiro, Brahm | en_US |
dc.contributor.author | Hutchinson, Raymond J. | en_US |
dc.date.accessioned | 2006-09-11T18:15:23Z | |
dc.date.available | 2006-09-11T18:15:23Z | |
dc.date.issued | 1991-03 | en_US |
dc.identifier.citation | Khafagi, Frederick A.; Shapiro, Brahm; Fischer, Manfred; Sisson, James C.; Hutchinson, Raymond; Beierwaltes, William H.; (1991). "Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine." European Journal of Nuclear Medicine 18(3): 191-198. <http://hdl.handle.net/2027.42/46831> | en_US |
dc.identifier.issn | 1619-7089 | en_US |
dc.identifier.issn | 0340-6997 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46831 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1645665&dopt=citation | en_US |
dc.description.abstract | Phaeochromocytomas and functioning paragangliomas are rare tumours in childhood and adolescence. We review our experience of 43 cases (24 men, 19 women) who were first diagnosed at the age of ⩽ 18 years. All patients were evaluated at some point in their illness with iodine 131 metaiodobenzylguanidine ( 131 I-mIBG) scintigraphy. Eight patients (19%) had bilateral adrenal tumours, 12 (28%) had solitary extra-adrenal tumours, and 8 (19%) had multiple tumours. In 10 patients (23%), the tumours were associated with a familial neurocristopathic syndrome. Thirteen of 24 (54%) unifocal tumours which were initially considered to be benign ultimately proved to be multi-focal and/or malignant. The final prevalence of malignancy was 60% − 26 patients, of whom only 15 (57%) had obviously malignant tumours at the time of diagnosis. Primary tumour size ⋝5 cm was more commonly associated with a malignant course in adrenal but not extra-adrenal tumours. No other clinical, biochemical or morphological characteristic was significantly associated with malignancy. Although the high prevalence of malignancy in this series at least partly reflects referral bias, the need for lifelong follow-up of these patients is underscored. 131 I-mIBG scintigraphy was positive in 36 patients (84%), with a somewhat lower false-negative rate (12%) than X-ray computed tomography (20%). Eight patients with malignant tumours received therapeutic doses of 131 I-mIBG, with partial tumour responses in 3. Thus, 131 I-mIBG is an efficacious, non-invasive, localising agent and may be considered as a palliative therapeutic agent when alternatives have failed. | en_US |
dc.format.extent | 844898 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Metaiodobenzylguanidine | en_US |
dc.subject.other | Phaeochromocytoma | en_US |
dc.subject.other | Imaging / Radiology | en_US |
dc.subject.other | Childhood | en_US |
dc.subject.other | Adolescence | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Nuclear Medicine | en_US |
dc.subject.other | Paraganglioma | en_US |
dc.title | Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Physics | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical Center, 48109-0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Division of Nuclear Medicine, Department of Internal Medicine, University Hospital, B1G 412, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Division of Nuclear Medicine, Department of Internal Medicine, University Hospital, B1G 412, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Division of Nuclear Medicine, Department of Internal Medicine, University Hospital, B1G 412, Ann Arbor, MI, USA; Department of Nuclear Medicine, Städtische Kliniken, Kassel, Germany | en_US |
dc.contributor.affiliationother | Division of Nuclear Medicine, Department of Internal Medicine, University Hospital, B1G 412, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Division of Nuclear Medicine, Department of Internal Medicine, University Hospital, B1G 412, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 1645665 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46831/1/259_2005_Article_BF02262730.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF02262730 | en_US |
dc.identifier.source | European Journal of Nuclear Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.